


Stereochemistry abstracts

Dieter Enders* and Giuseppe Del Signore

Tetrahedron: Asymmetry 15 (2004) 747




C₁₅H₁₇NO₂S
(S)-(1-Thiophen-2-yl-propyl)-carbamic acid benzyl ester

Ee = 99% (Chiral HPLC)
[α]_D²⁵ = -57.8 (c 1.4, CHCl₃)

Dieter Enders* and Giuseppe Del Signore

Tetrahedron: Asymmetry 15 (2004) 747




C₁₇H₂₁NO₂S
(S)-(2,2-Dimethyl-1-thiophen-3-yl-propyl)-carbamic acid benzyl ester

Ee = 93% (Chiral HPLC)
[α]_D²⁵ = -8.1 (c 1.5, CHCl₃)

Dieter Enders* and Giuseppe Del Signore

Tetrahedron: Asymmetry 15 (2004) 747




C₁₆H₂₀N₂O₂
(S)-[1-(1-Methyl-1H-pyrrol-2-yl)-propyl]-carbamic acid benzyl ester

Ee = 88% (Chiral HPLC)
[α]_D²⁵ = -62.4 (c 1.8, CHCl₃)


Dieter Enders* and Giuseppe Del Signore

Tetrahedron: Asymmetry 15 (2004) 747




C₁₅H₁₇NO₂S
(S)-(1-Thiophen-3-yl-propyl)-carbamic acid benzyl ester

Ee = 94% (Chiral HPLC)
[α]_D²⁵ = -47.4 (c 1.1, CHCl₃)




$C_{15}H_{16}N_2O$
(1*S*)-*N*-(1-Pyridin-2-yl-propyl)-benzamide

Ee = 96% (Chiral HPLC)
 $[\alpha]_D^{25} = -16.0$ (*c* 1.0, CHCl₃)




$C_{15}H_{16}N_2O$
(1*S*)-*N*-(1-Pyridin-3-yl-propyl)-benzamide

Ee = 96% (Chiral HPLC)
 $[\alpha]_D^{25} = +11.7$ (*c* 1.4, CHCl₃)




$C_{19}H_{20}N_2O$
(1*S*)-*N*-[1-(1-Methyl-1*H*-indol-2-yl)-propyl]-benzamide

Ee = 94% (Chiral HPLC)
 $[\alpha]_D^{25} = -120.2$ (*c* 1.6, CHCl₃)




$C_{14}H_{17}N_3O$
(1*S*)-*N*-[1-(1-Methyl-1*H*-imidazol-2-yl)-propyl]-benzamide

Ee = 99% (Chiral HPLC)
 $[\alpha]_D^{25} = -25.0$ (*c* 1.2, CHCl₃)




$C_{18}H_{17}NO_2$
(1*S*)-*N*-(1-Benzofuran-2-yl-propyl)-benzamide

Ee = 97% (Chiral HPLC)
 $[\alpha]_D^{25} = -85.4$ (*c* 0.9, CHCl₃)




$C_{14}H_{15}NO_2$
(1*S*)-*N*-(1-Furan-2-yl-propyl)-benzamide

Ee = 99% (Chiral HPLC)
 $[\alpha]_D^{25} = -62.4$ (*c* 1.1, CHCl₃)




$C_{16}H_{19}NO_2$
(1*S*)-*N*-(1-Furan-2-yl-2,2-dimethylpropyl)-benzamide

Ee = 98% (Chiral HPLC)
 $[\alpha]_D^{25} = -43.0$ (*c* 1.3, CHCl₃)



$C_{14}H_{27}NO$
1-[2-(Dimethylamino)ethyl]-2,3,3-trimethylnorbornan-2-ol

$[\alpha]_D^{20} = +15.4$ (*c* 2.20, CHCl₃)
Source of chirality: natural (−)-(1*R*)-fenchone
Absolute configuration: (1*R*,2*R*)




$C_{26}H_{29}N_2OPS$
1-(Diphenyl-phosphinothioyl)-2-(3'-isopropyl-4',5'-dihydro-oxazo-2'-yl)-2,3-dihydro-1H-indole

$[\alpha]_D = -57.4$ (*c* 0.012, CHCl₃)

Source of chirality: L-indoline carboxylic acid,
L-valinol

Absolute configuration: 2*S*,3'*S*




$C_{26}H_{29}N_2OPS$
1-(Diphenyl-phosphinothioyl)-2-(3'-isopropyl-4',5'-dihydro-oxazo-2'-yl)-2,3-dihydro-1H-indole

$[\alpha]_D = -10.4$ (*c* 0.012, CHCl₃)

Source of chirality: L-indoline carboxylic acid,
D-valinol

Absolute configuration: 2*S*,3'*R*




$C_{11}H_{15}ClO_2$
(2*R*)-(-)-1-Chloro-3-(2,5-dimethylphenoxy)propan-2-ol

Ee = 99%

$[\alpha]_D^{25} = -7.2$ (*c* 0.46, EtOH)

Source of chirality: enzymatic reduction of ketone
Absolute configuration: 2*R*




(2*R*)-(+)-1-Chloro-3-phthalimidyl-propan-2-ol

Ee = 93%

$[\alpha]_D^{25} = +16.2$ (*c* 0.48, EtOH)


Source of chirality: enzymatic reduction of ketone
Absolute configuration: 2*R*


 $[\alpha]_D^{20} = +108.8 \text{ (c } 2.15, \text{ CHCl}_3\text{)}$

Source of chirality: enzymatic resolution

Absolute configuration: (1*S*,2*S*,5*S*,6*S*)


$\text{C}_{10}\text{H}_{14}\text{O}_2$
(1*S*,2*S*,5*S*,6*S*)-Bicyclo[3.3.0]octan-2,6-dione diepoxide


 $[\alpha]_D^{20} = +56.5 \text{ (c } 0.85, \text{ CHCl}_3\text{)}$

Source of chirality: enzymatic resolution,

(R)-1-phenylethylamineAbsolute configuration: (1*S*,2*S*,5*S*,6*S*,1'*R*,1''*R*)


$\text{C}_{16}\text{H}_{36}\text{N}_2\text{O}_2$
(1*S*,2*S*,5*S*,6*S*,1'*R*,1''*R*)-2,6-Bis(1-phenylethyl-amino-methyl)-bicyclo[3.3.0]octan-2,6-diol


 $[\alpha]_D^{20} = -12.5 \text{ (c } 3.20, \text{ CHCl}_3\text{)}$

Source of chirality: enzymatic resolution,

(S)-1-phenylethylamineAbsolute configuration: (1*S*,2*S*,5*S*,6*S*,1'*S*,1''*S*)


$\text{C}_{16}\text{H}_{36}\text{N}_2\text{O}_2$
(1*S*,2*S*,5*S*,6*S*,1'*S*,1''*S*)-2,6-Bis(1-phenylethyl-amino-methyl)-bicyclo[3.3.0]octan-2,6-diol


 $[\alpha]_D^{20} = +63.6 \text{ (c } 1.15, \text{ CHCl}_3\text{)}$

Source of chirality: enzymatic resolution

Absolute configuration: (1*S*,5*S*,6*S*)

$\text{C}_{11}\text{H}_{16}\text{O}_3$
(1*S*,5*S*,6*S*)-Bicyclo[3.3.0]octan-2,6-dione 2-epoxide 6-ethylene ketal


 $[\alpha]_D^{20} = +70.7 \text{ (c } 1.35, \text{ CHCl}_3)$


Source of chirality: enzymatic resolution,

(R)-1-phenylethylamine

Absolute configuration: (1S,5S,6S,1'R)

 $C_{18}H_{24}NO_3$

(1S,5S,6S,1'R)-6-Hydroxy-6-(1-phenylethyl-amino-methyl)-bicyclo[3.3.0]octan-2-one ethylene ketal


 $[\alpha]_D^{20} = +146.5 \text{ (c } 0.85, \text{ CHCl}_3)$


Source of chirality: enzymatic resolution,

(R)-1-phenylethylamine

Absolute configuration: (1S,5S,6S,1'R)

 $C_{17}H_{23}NO_2$

(1S,5S,6S,1'R)-6-Hydroxy-6-(1-phenylethyl-amino-methyl)-bicyclo[3.3.0]octan-2-one



 $[\alpha]_D^{20} = -111.6 \text{ (c } 1.20, \text{ CHCl}_3)$

Source of chirality: enzymatic resolution

Absolute configuration: (1R,2R,5R,6R)

 $C_{10}H_{14}O_2$

(1R,2R,5R,6R)-Bicyclo[3.3.0]octan-2,6-dione diepoxide


 $[\alpha]_D^{20} = -53.0 \text{ (c } 1.55, \text{ CHCl}_3)$


Source of chirality: enzymatic resolution,

(S)-1-phenylethylamine

Absolute configuration: (1R,2R,5R,6R,1'S,1''S)

 $C_{16}H_{36}N_2O_2$

(1R,2R,5R,6R,1'S,1''S)-2,6-Bis(1-phenylethyl-amino-methyl)-bicyclo[3.3.0]octan-2,6-diol




Ee >98%

 $[\alpha]_D^{20} = -87.94$ (*c* 0.6, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: (*S*) $C_{10}H_{14}O_4$

(S)-4-Methoxy-3-methyl-2-oxocyclohex-3-en-1-yl acetate




Ee = 96%

 $[\alpha]_D^{20} = +167.3$ (*c* 0.3, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: (*R*) $C_8H_{12}O_3$

(R)-6-Hydroxy-3-methoxy-2-methylcyclohex-2-en-1-one




Ee = 98%

 $[\alpha]_D^{20} = +32.1$ (*c* 0.01, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: (*R*) $C_9H_{12}O_4$

(R)-4-Methoxy-3-methyl-2-oxocyclopent-3-en-1-yl acetate




Ee = 95%

 $[\alpha]_D^{20} = +78.8$ (*c* 0.1, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: (*S*) $C_7H_{10}O_3$

(S)-5-Hydroxy-3-methoxy-2-methylcyclopent-2-en-1-one




C₇H₁₀O₂
(R)-4-Hydroxy-2-methylcyclohex-2-en-1-one

Ee = 98%

[α]_D²⁰ = +46.7 (c 0.1, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: (R)




C₆H₈O₂
(S)-4-Hydroxy-2-methylcyclopent-2-en-1-one

Ee = 95%

[α]_D²⁰ = -33.5 (c 1.1, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: (S)




C₁₃H₂₀O₂Se
(R)-Camphorseleenoacetone

[α]_D²⁰ = +18.3 (c 1.2, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: R




C₁₃H₂₀O₃Se
Methyl (R)-camphorseleenoacetate

[α]_D²⁵ = -23.9 (c 3.2, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: R




$C_{20}H_{26}O_3Se$
(*3R,4S*)-3-(Camphorseleno)-4-hydroxy-4-phenylbutan-2-one

$[\alpha]_D^{20} = +70.0$ (*c* 2.4, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 3*R*,4*S*




$C_{22}H_{30}O_3Se$
(*3R,4S*)-3-(Camphorseleno)-4-hydroxy-6-phenylhexan-2-one

$[\alpha]_D^{21} = +47.3$ (*c* 2.7, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 3*R*,4*S*




$C_{22}H_{30}O_4Se$
(*3R,4S*)-5-(Benzylxy)-3-(camphorseleno)-4-hydroxypentan-2-one

$[\alpha]_D^{22} = +49.3$ (*c* 1.4, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 3*R*,4*S*




$C_{20}H_{26}O_4Se$
Methyl (*2R,3S*)-2-(camphorseleno)-3-hydroxy-3-phenylpropanoate

$[\alpha]_D^{25} = -41.2$ (*c* 1.5, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*R*,3*S*




$C_{21}H_{28}O_5Se$
Methyl (2*R*,3*S*)-2-(camphorseleno)-3-hydroxy-3-(4-methoxyphenyl)propanoate

$[\alpha]_D^{26} = -40.4$ (*c* 2.0, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*R*,3*S*




$C_{22}H_{28}O_4Se$
Methyl (2*R*,3*S*,4*E*)-2-(camphorseleno)-3-hydroxy-5-phenylpent-4-enoate

$[\alpha]_D^{23} = -58.1$ (*c* 1.6, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*R*,3*S*




$C_{22}H_{30}O_4Se$
Methyl (2*R*,3*S*)-2-(camphorseleno)-3-hydroxy-5-phenylpentanoate

$[\alpha]_D^{17} = -41.6$ (*c* 3.5, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*R*,3*S*




$C_{20}H_{26}O_3Se$
(3*S*,4*R*)-3-(Camphorseleno)-4-hydroxy-4-phenylbutan-2-one

$[\alpha]_D^{22} = -125.0$ (*c* 0.4, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 3*S*,4*R*




$C_{22}H_{30}O_3Se$
(*3S,4R*)-3-(Camphorseleno)-4-hydroxy-6-phenylhexan-2-one

$[\alpha]_D^{24} = -105.7$ (*c* 0.4, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 3*S*,4*R*




$C_{22}H_{30}O_4Se$
(*3S,4R*)-5-(Benzylxy)-3-(camphorseleno)-4-hydroxypentan-2-one

$[\alpha]_D^{24} = -64.9$ (*c* 0.5, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 3*S*,4*R*




$C_{20}H_{26}O_4Se$
Methyl (*2S,3R*)-2-(camphorseleno)-3-hydroxy-3-phenylpropanoate

$[\alpha]_D^{26} = -86.4$ (*c* 2.5, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*R*




$C_{21}H_{28}O_5Se$
Methyl (*2S,3R*)-2-(camphorseleno)-3-hydroxy-3-(4-methoxyphenyl)propanoate

$[\alpha]_D^{26} = -51.3$ (*c* 1.3, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: 2*S*,3*R*




$[\alpha]_D^{24} = -50.4$ (*c* 2.5, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*R*




Methyl (2*S*,3*R*,4*E*)-2-(camphorseleno)-3-hydroxy-5-phenylpent-4-enoate




$[\alpha]_D^{19} = -79.5$ (*c* 1.7, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*R*




Methyl (2*S*,3*R*)-2-(camphorseleno)-3-hydroxy-5-phenylpentanoate




$[\alpha]_D^{24} = +56.1$ (*c* 0.9, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 3*R*,4*R*



(3*R*,4*R*)-3-(Camphorseleno)-4-hydroxy-4-phenylbutan-2-one




M.p. 90–91 °C

$[\alpha]_D^{19} = -113.5$ (*c* 1.7, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: 4*R*,5*S*,6*S*



(4*R*,5*S*,6*S*)-5-(Camphorseleno)-2,2,4-trimethyl-6-phenyl-1,3-dioxane

Marcello Tiecco,* Lorenzo Testaferri, Francesca Marini,
Silvia Sternativo, Claudio Santi, Luana Bagnoli and Andrea Temperini

Tetrahedron: Asymmetry 15 (2004) 783



$[\alpha]_D^{24} = +8.0$ (*c* 0.8, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: 2*R*, (*R*)



Methyl (2*R*)-2-[(*R*)-hydroxy(phenyl)methyl]pent-4-enoate

Marcello Tiecco,* Lorenzo Testaferri, Francesca Marini,
Silvia Sternativo, Claudio Santi, Luana Bagnoli and Andrea Temperini

Tetrahedron: Asymmetry 15 (2004) 783



$[\alpha]_D^{25} = +26.7$ (*c* 0.5, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*, (*R*)



Methyl (2*S*)-2-[(*R*)-hydroxy(phenyl)methyl]pent-4-enoate

Gary P. Reid, Kieron W. Brear and David J. Robins*


Tetrahedron: Asymmetry 15 (2004) 793

Ee 92%

$[\alpha]_D = +17.7$ (*c* 2.9, EtOAc)

Source of chirality: asymmetric synthesis


Absolute configuration: 2*R*



(2*R*)-2-Benzylsuccinic acid

Morris Markert, Ingo Buchem, Hannes Krüger and Rainer Mahrwald*

Tetrahedron: Asymmetry 15 (2004) 803




$[\alpha]_D^{25} = +96$ (*c* 1, ethylacetate)

Source of chirality: (*R,R*)-tartaric acid

Absolute configuration: 2*R*,2*'R*,5*R*,5*'R*



(2*R*,2*'R*,5*R*,5*'R*)-2,2'-Dimethyl-5,5'-bis(1,3-dioxolane-4,4'-dione)




$C_{10}H_{14}O_6$
($2R,2'R,5R,5'R$)- $2,2'$ -Diethyl-5,5'-bis(1,3-dioxolane-4,4'-dione)

$[\alpha]_D^{25} = +35$ (c 0.64, CH_2Cl_2)

Source of chirality: (R,R)-tartaric acid

Absolute configuration: $2R,2'R,5R,5'R$




$C_{12}H_{18}O_6$
($2R,2'R,5R,5'R$)- $2,2'$ -Dipropyl-5,5'-bis(1,3-dioxolane-4,4'-dione)

$[\alpha]_D^{25} = +61$ (c 0.64, CH_2Cl_2)

Source of chirality: (R,R)-tartaric acid

Absolute configuration: $2R,2'R,5R,5'R$




$C_{14}H_{22}O_6$
($2R,2'R,5R,5'R$)- $2,2'$ -Ditertbutyl-5,5'-bis(1,3-dioxolane-4,4'-dione)

$[\alpha]_D^{25} = +18$ (c 1, Et_2O)

Source of chirality: (R,R)-tartaric acid

Absolute configuration: $2R,2'R,5R,5'R$




$C_{18}H_{26}O_6$
($2S,2'S,5S,5'S$)- $2,2'$ -Dicyclohexyl-5,5'-bis(1,3-dioxolane-4,4'-dione)


$[\alpha]_D^{25} = -46$ (c 1, CH_2Cl_2)

Source of chirality: (S,S)-tartaric acid


Absolute configuration: $2S,2'S,5S,5'S$


 $[\alpha]_D^{25} = -65$ (*c* 1.04, CH₂Cl₂)
Source of chirality: (*S,S*)-tartaric acidAbsolute configuration: 2*S*,2'*R*,5*S*,5'*S*


C₁₀H₁₄O₆
(2*S*,2'*R*,5*S*,5'*S*)-2,2'-Diethyl-5,5'-bis(1,3-dioxolane-4,4'-dione)


 $[\alpha]_D^{25} = +33$ (*c* 0.04, CH₂Cl₂)
Source of chirality: (*R,R*)-tartaric acidAbsolute configuration: 2*S*,2'*R*,5*R*,5'*R*


C₁₂H₁₈O₆
(2*S*,2'*R*,5*R*,5'*R*)-2,2'-Dipropyl-5,5'-bis(1,3-dioxolane-4,4'-dione)


 $[\alpha]_D^{25} = +38$ (*c* 0.16, CH₂Cl₂)
Source of chirality: (*R,R*)-tartaric acidAbsolute configuration: 2*S*,2'*R*,5*R*,5'*R*

C₁₂H₁₈O₆
(2*S*,2'*R*,5*R*,5'*R*)-2,2'-Diisopropyl-5,5'-bis(1,3-dioxolane-4,4'-dione)


 $[\alpha]_D^{25} = +49$ (*c* 0.26, CH₂Cl₂)
Source of chirality: (*R,R*)-tartaric acidAbsolute configuration: 2*S*,2'*R*,5*R*,5'*R*

C₁₄H₂₂O₆
(2*S*,2'*R*,5*R*,5'*R*)-2,2'-Ditertbutyl-5,5'-bis(1,3-dioxolane-4,4'-dione)




$C_{18}H_{26}O_6$
($2S,2'R,5R,5'R$)- $2,2'$ -Dicyclohexyl- $5,5'$ -bis(1,3-dioxolane-4,4'-dione)

$[\alpha]_D^{25} = +24$ (c 0.26, CH_2Cl_2)

Source of chirality: (R,R)-tartaric acid

Absolute configuration: $2S,2'R,5R,5'R$




$C_{12}H_{18}O_6$
($2S,2'S,5S,5'S$)- $2,2'$ -Diisopropyl- $5,5'$ -bis(1,3-dioxolane-4,4'-dione)

$[\alpha]_D^{25} = -50$ (c 0.8, CH_2Cl_2)

Source of chirality: (S,S)-tartaric acid

Absolute configuration: $2S,2'S,5S,5'S$




$C_8H_{10}O_2$
1-Phenyl-ethane-1,2-diol

Ee = 96%

$[\alpha]_D^{20} = +66.7$ (c 1.05, $CHCl_3$)

Source of chirality: asymmetric reduction

Absolute configuration: (S)




$C_8H_9FO_2$
1-(4-Fluoro-phenyl)-ethane-1,2-diol

Ee = 97%

$[\alpha]_D^{20} = 57.2$ (c 0.996, $CHCl_3$)

Source of chirality: asymmetric reduction

Absolute configuration: (S)




C₈H₉ClO₂
1-(4-Chloro-phenyl)-ethane-1,2-diol

Ee = 98%

[α]_D²² = +57.8 (c 1.082, CHCl₃)

Source of chirality: asymmetric reduction

Absolute configuration: (S)




C₈H₉BrO₂
1-(4-Bromo-phenyl)-ethane-1,2-diol

Ee = 94%

[α]_D¹⁷ = +33.3 (c 2.134, acetone)

Source of chirality: asymmetric reduction

Absolute configuration: (S)




C₉H₁₂O₂
1-p-Tolyl-ethane-1,2-diol

Ee = 95%

[α]_D¹⁶ = +66 (c 0.934, CHCl₃)

Source of chirality: asymmetric reduction

Absolute configuration: (S)




C₉H₁₂O₃
1-(4-Methoxy-phenyl)-ethane-1,2-diol

Ee = 95%

[α]_D¹⁶ = +63.1 (c 0.914, CHCl₃)

Source of chirality: asymmetric reduction

Absolute configuration: (S)




$C_6H_{14}O_2$
3,3-Dimethyl-butane-1,2-diol

Ee = 94%

$[\alpha]_D^{12} = +13.1$ (*c* 0.731, CHCl₃)

Source of chirality: asymmetric reduction

Absolute configuration: (*S*)




$C_6H_{14}O_2$
1,2-Hexane-diol

Ee = 45%

$[\alpha]_D^9 = -6.1$ (*c* 1.30, ethanol)

Source of chirality: asymmetric reduction

Absolute configuration: (*S*)




$C_{10}H_{14}O_2$
4-Phenyl-butane-1,2-diol

Ee = 62%

$[\alpha]_D^{17} = -11.3$ (*c* 0.702, ethanol)

Source of chirality: asymmetric reduction

Absolute configuration: (*S*)




$C_8H_{16}O_2$
cyclo-Hexyl-ethane-1,2-diol

Ee = 86%

$[\alpha]_D^{20} = +4.4$ (*c* 1.068, CHCl₃)

Source of chirality: asymmetric reduction


Absolute configuration: (*S*)



C₉H₁₂O₂
1-*o*-Tolyl-ethane-1,2-diol


Ee = 75%
[α]_D²⁰ = +57.9 (*c* 1.195, CHCl₃)

Source of chirality: asymmetric reduction
Absolute configuration: (S)




C₉H₁₂O₂
1-*m*-Tolyl-ethane-1,2-diol

Ee = 94%
[α]_D²⁰ = +55.2 (*c* 2.25, CHCl₃)
Source of chirality: asymmetric reduction
Absolute configuration: undetermined




C₂₁H₂₁NO₃
Methyl (1*S*,2*S*,4*R*)-*N*-benzoyl-2-phenyl-7-azabicyclo[2.2.1]heptane-1-carboxylate

Ee >98%
[α]_D²⁵ = +52.9 (*c* 1.0, CHCl₃)
Source of chirality: resolution by chiral HPLC
Absolute configuration: (1*S*,2*S*,4*R*)



C₂₀H₁₉NO₃
(1*S*,2*S*,4*R*)-*N*-Benzoyl-2-phenyl-7-azabicyclo[2.2.1]heptane-1-carboxylic acid

Ee >98%
[α]_D²⁵ = +82.6 (*c* 0.5, CHCl₃)
Source of chirality: resolution by chiral HPLC
Absolute configuration: (1*S*,2*S*,4*R*)




$C_{13}H_{16}ClNO_2$
(1*S*,2*S*,4*R*)-2-Phenyl-7-azabicyclo[2.2.1]heptane-1-carboxylic acid hydrochloride

Ee >98%

 $[\alpha]_D^{25} = -23.8$ (*c* 0.5, CHCl₃)

Source of chirality: resolution by chiral HPLC


Absolute configuration: (1*S*,2*S*,4*R*)

$C_{32}H_{35}N_3O_3$
(1*S*,2*S*,4*R*)-N-Benzoyl-2-phenyl-7-azabicyclo[2.2.1]heptane-1-carbonyl-(S)-N'-isopropylphenylalaninamide

Ee >98%

 $[\alpha]_D^{25} = +96.2$ (*c* 0.5, CHCl₃)

Source of chirality: resolution by chiral HPLC


Absolute configuration: (1*S*,2*S*,4*R*)-(S)

$C_{32}H_{35}N_3O_3$
(1*R*,2*R*,4*S*)-N-Benzoyl-2-phenyl-7-azabicyclo[2.2.1]heptane-1-carbonyl-(S)-N'-isopropylphenylalaninamide

Ee >98%

 $[\alpha]_D^{25} = -44.7$ (*c* 0.36, CHCl₃)

Source of chirality: resolution by chiral HPLC

Absolute configuration: (1*R*,2*R*,4*S*)-(S)


$C_{16}H_{17}NO_5$
(1*S*,2*R*,4*R*)-N-Benzoyl-1-carbomethoxy-7-azabicyclo[2.2.1]heptane-2-carboxylic acid

Ee >98%

 $[\alpha]_D^{25} = -18.8$ (*c* 0.5, CHCl₃); $[\alpha]_D^{25} = -24.1$ (*c* 0.2, MeOH)

Source of chirality: resolution by chiral HPLC

Absolute configuration: (1*S*,2*R*,4*R*)




$C_8H_{12}ClNO_4$
(1*S*,2*R*,4*R*)-7-Azabicyclo[2.2.1]heptane-1,2-dicarboxylic acid hydrochloride

Ee >98%

 $[\alpha]_D^{25} = -28.0$ (*c* 0.20, H₂O)

Source of chirality: resolution by chiral HPLC


Absolute configuration: (1*S*,2*R*,4*R*)

$C_{16}H_{19}NO_4$
Methyl (1*S*,2*R*,4*R*)-*N*-benzoyl-2-hydroxymethyl-7-azabicyclo[2.2.1]heptane-1-carboxylate

Ee >98%

 $[\alpha]_D^{25} = -40.7$ (*c* 1.0, CHCl₃)

Source of chirality: resolution by chiral HPLC


Absolute configuration: (1*S*,2*R*,4*R*)

$C_{16}H_{17}NO_4$
Methyl (1*S*,2*R*,4*R*)-*N*-benzoyl-2-formyl-7-azabicyclo[2.2.1]heptane-1-carboxylate

Ee >98%

 $[\alpha]_D^{25} = -7.1$ (*c* 1.0, CHCl₃)

Source of chirality: resolution by chiral HPLC

Absolute configuration: (1*S*,2*R*,4*R*)

$C_6H_{12}O_3$
Ethyl (S)-3-hydroxybutyrate


Ee >98%

 $[\alpha]_D = -44.5$ (*c* 1, CHCl₃)

Source of chirality: stereoinversion of

(R)-mesylate

Absolute configuration: 3(S)




Ee >99% (by HPLC)


$[\alpha]_D^{20} = -49.8$ (*c* 0.47, CH₂Cl₂)

Source of chirality: enzymatic resolution

Absolute configuration: (*S*)



(*-*)-(3*S*)-Diethyl 3-hydroxy-1-cyclopentenyl phosphonate



Ee = 84% (by HPLC)


$[\alpha]_D^{20} = +94.1$ (*c* 0.49, CH₂Cl₂)

Source of chirality: enzymatic resolution

Absolute configuration: (*R*)



(*+*)-(3*R*)-Diethyl 3-acetoxy-1-cyclopentenyl phosphonate




Ee >99% (by HPLC)


$[\alpha]_D^{20} = -34.6$ (*c* 0.50, CH₂Cl₂)

Source of chirality: enzymatic resolution

Absolute configuration: (*S*)



(*-*)-(3*S*)-Diethyl 3-hydroxy-1-cyclohexenyl phosphonate



Ee >99% (by HPLC)


$[\alpha]_D^{20} = +91.3$ (*c* 0.51, CH₂Cl₂)

Source of chirality: enzymatic resolution

Absolute configuration: (*R*)



(*+*)-(3*R*)-Diethyl 3-acetoxy-1-cyclohexenyl phosphonate




Ee >99% (by HPLC)


$[\alpha]_D^{20} = +9.9$ (*c* 0.49, CH₂Cl₂)

Source of chirality: enzymatic resolution

Absolute configuration: (*S*)



(+)-(3*S*)-Diethyl 3-hydroxy-1-cycloheptenyl phosphonate




Ee >99% (by HPLC)


$[\alpha]_D^{20} = +15.5$ (*c* 0.50, CH₂Cl₂)

Source of chirality: enzymatic resolution

Absolute configuration: (*R*)



(+)-(3*R*)-Diethyl 3-acetoxy-1-cycloheptenyl phosphonate



Ee = 61% (by correlation)

$[\alpha]_D^{20} = -38.4$ (*c* 0.59, CH₂Cl₂)


Source of chirality: enzymatic resolution

Absolute configuration: (*S*)




(-)-(3*S*)-3-Bromo-1-cyclopentenol

$[\alpha]_D^{23} = +200$ (*c* 1, CH₂Cl₂)




C₂₀H₂₀O₅S
3,5-Di-O-benzyl-1,2-O-thiocarbonyl- α -D-ribo-furanose

$[\alpha]_D^{23} = +170$ (*c* 1, CH₂Cl₂)




C₂₀H₁₆O₇S
3,5-Di-*O*-benzoyl-1,2-*O*-thiocarbonyl- α -D-*ribo*-furanose

$[\alpha]_D^{23} = +164$ (*c* 1, CH₂Cl₂)




C₂₇H₂₅N₃O₁₀S
1-(2'-*O*-Acetamidomercaptocarbonyl-3',5'-di-*O*-benzoyl- β -D-*xylo*-furanosyl)thymine

$[\alpha]_D^{23} = +147$ (*c* 1, CH₂Cl₂)




C₂₆H₂₃N₃O₁₀S
1-(2'-*O*-Acetamidomercaptocarbonyl-3',5'-di-*O*-benzoyl- β -D-*xylo*-furanosyl)uracil

$[\alpha]_D^{23} = +156$ (*c* 1, CH₂Cl₂)




C₂₆H₂₂N₃O₁₀FS
1-(2'-*O*-Acetamidomercaptocarbonyl-3',5'-di-*O*-benzoyl- β -D-*xylo*-furanosyl)-5-fluorouracil




$[\alpha]_D^{23} = +67$ (*c* 1, CH₂Cl₂)

C₂₇H₂₉N₃O₈S
1-(2'-O-Acetamidomercaptocarbonyl-3',5'-di-O-benzyl-beta-D-ribo-furanosyl)thymine




$[\alpha]_D^{23} = +92$ (*c* 1, CH₂Cl₂)

C₂₆H₂₇N₃O₈S
1-(2'-O-Acetamidomercaptocarbonyl-3',5'-di-O-benzyl-beta-D-ribo-furanosyl)uracil




$[\alpha]_D^{23} = +98$ (*c* 1, CH₂Cl₂)

C₂₆H₂₆N₃O₈FS
1-(2'-O-Acetamidomercaptocarbonyl-3',5'-di-O-benzyl-beta-D-ribo-furanosyl)-5-fluorouracil




$[\alpha]_D^{23} = -59$ (*c* 1, CH₂Cl₂)

C₂₇H₂₅N₃O₁₀S
1-(2'-O-Acetamidomercaptocarbonyl-3',5'-di-O-benzoyl-beta-D-ribo-furanosyl)thymine




C₂₆H₂₃N₃O₁₀S
1-(2'-O-Acetamidomercaptocarbonyl-3',5'-di-O-benzoyl-β-D-ribo-furanosyl)uracil

Mp 171–172 °C
[α]_D²³ = −43 (c 1, CH₂Cl₂)




C₂₆H₂₂N₃O₁₀FS
1-(2'-O-Acetamidomercaptocarbonyl-3',5'-di-O-benzoyl-β-D-ribo-furanosyl)-5-fluorouracil

Mp 202–203 °C
[α]_D²³ = −32 (c 1, CH₂Cl₂)




C₂₃H₂₃N₂O₆F
1-(3',5'-Di-O-benzyl-β-D-xylo-furanosyl)-5-fluorouracil

Mp 103–104 °C
[α]_D²³ = −4 (c 6, CH₂Cl₂)




C₂₃H₂₃N₂O₆F
1-(3',5'-Di-O-benzyl-β-D-ribo-furanosyl)-5-fluorouracil

[α]_D²³ = +19 (c 1, CH₂Cl₂)




$C_{24}H_{22}N_2O_{10}S$
1-(3',5'-Di-O-benzoyl-2'-O-mesyl- β -D-xylo-furanosyl)uracil

Mp 63–64 °C
 $[\alpha]_D^{23} = +64$ (*c* 1, acetone)




$C_{14}H_{16}O_5$
(2*R*,3*S*)-2,3-Dihydroxy-3-methylpent-4-yn-1-yl *p*-methoxybenzoate

Ee = 95%
 $[\alpha]_D^{24} = +32.9$ (*c* 0.37, MeOH)
Source of chirality: asymmetric synthesis
Absolute configuration: 2*R*,3*S*




$C_{14}H_{16}O_5$
(2*R*,3*R*)-2,3-Dihydroxy-3-methylpent-4-yn-1-yl *p*-methoxybenzoate

Ee = 94%
 $[\alpha]_D^{24} = +29.9$ (*c* 1.27, MeOH)
Source of chirality: asymmetric synthesis
Absolute configuration: 2*R*,3*R*




$C_{14}H_{16}O_5$
(2*S*,3*R*)-2,3-Dihydroxy-3-methylpent-4-yn-1-yl *p*-methoxybenzoate


Ee = 87%
 $[\alpha]_D^{24} = -25.6$ (*c* 0.42, MeOH)
Source of chirality: asymmetric synthesis
Absolute configuration: 2*S*,3*R*

 $Ee = 96\%$ $[\alpha]_D^{24} = -28.7$ (*c* 0.74, MeOH)


Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*S* $C_{14}H_{16}O_5$ (2*S*,3*S*)-2,3-Dihydroxy-3-methylpent-4-yn-1-yl *p*-methoxybenzoate $[\alpha]_D^{24} = +12.5$ (*c* 0.008, MeOH)

Source of chirality: asymmetric synthesis


Absolute configuration: 2*R*,3*R*,4*E* $C_{16}H_{44}O_5Sn$ (2*R*,3*R*,4*E*)-2,3-Dihydroxy-3-methyl-5-(tri-*n*-butylstannyl)-pent-4-yn-1-yl *p*-methoxybenzoate $[\alpha]_D^{24} = -14.8$ (*c* 0.027, MeOH).

Source of chirality: asymmetric synthesis


Absolute configuration: 2*S*,3*R*,4*E* $C_{26}H_{44}O_5Sn$ (2*S*,3*R*,4*E*)-2,3-Dihydroxy-3-methyl-5-(tri-*n*-butylstannyl)-pent-4-yn-1-yl *p*-methoxybenzoate $[\alpha]_D^{24} = -24.9$ (*c* 0.15, MeOH)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*S*,4*E* $C_{26}H_{44}O_5Sn$ (2*S*,3*S*,4*E*)-2,3-Dihydroxy-3-methyl-5-(tri-*n*-butylstannyl)-pent-4-yn-1-yl *p*-methoxybenzoate

 $[\alpha]_D^{24} = +20.8$ (*c* 0.24, MeOH)


Source of chirality: asymmetric synthesis

Absolute configuration: 2*R*,3*S*,4*E* $C_{26}H_{44}O_5Sn$ (2*R*,3*S*,4*E*)-2,3-Dihydroxy-3-methyl-5-(tri-*n*-butylstannyl)-pent-4-yn-1-yl *p*-methoxybenzoate

Ee = 94%

 $[\alpha]_D^{24} = +14.9$ (*c* 0.003, MeOH)


Source of chirality: asymmetric synthesis

Absolute configuration: 13*R*,14*R* $C_{28}H_{38}O_5$ (13*R*,14*R*)-13,14-Dihydroxyretinol *p*-methoxybenzoate

Ee = 88%

 $[\alpha]_D^{24} = -22.7$ (*c* 0.022, MeOH)

Source of chirality: asymmetric synthesis


Absolute configuration: 13*R*,14*S* $C_{28}H_{38}O_5$ (13*R*,14*S*)-13,14-Dihydroxyretinol *p*-methoxybenzoate

Ee = 96%

 $[\alpha]_D^{24} = -16.6$ (*c* 0.036, MeOH)

Source of chirality: asymmetric synthesis

Absolute configuration: 13*S*,14*S* $C_{28}H_{38}O_5$ (13*S*,14*S*)-13,14-Dihydroxyretinol *p*-methoxybenzoate




$C_{28}H_{38}O_5$
(13*S*,14*R*)-13,14-Dihydroxyretinol *p*-methoxybenzoate

Ee = 94%

 $[\alpha]_D^{24} = +27.7$ (*c* 0.018, MeOH)


Source of chirality: asymmetric synthesis

Absolute configuration: 13*S*,14*R*

$C_{20}H_{32}O_3$
(13*R*,14*R*)-13,14-Dihydroxyretinol

 $[\alpha]_D^{24} = -11.5$ (*c* 0.026, MeOH).


Source of chirality: asymmetric synthesis

Absolute configuration: 13*R*,14*R*

$C_{20}H_{32}O_3$
(13*R*,14*S*)-13,14-Dihydroxyretinol

 $[\alpha]_D^{24} = +9.9$ (*c* 0.04, MeOH)

Source of chirality: asymmetric synthesis


Absolute configuration: 13*R*,14*S*

$C_{20}H_{32}O_3$
(13*S*,14*S*)-13,14-Dihydroxyretinol

 $[\alpha]_D^{24} = +14.3$ (*c* 0.06, MeOH)

Source of chirality: asymmetric synthesis

Absolute configuration: 13*S*,14*S*




$C_{20}H_{32}O_3$
(13*S*,14*R*)-13,14-Dihydroxyretinol

$[\alpha]_D^{24} = -13.3$ (*c* 0.03, MeOH)

Source of chirality: asymmetric synthesis

Absolute configuration: 13*S*,14*R*




$C_{14}H_{19}NOS$
(1'*R*,6*S*)-(-)-1-(2'-Hydroxy-1'-phenyl-ethyl)-6-methyl-piperidine-2-thione

White solid

$[\alpha]_D^{20} = -172.2$ (*c* 1.1, CH_2Cl_2)


$M_p = 107\text{--}110$ °C



$C_{16}H_{23}NOS$
(1'*R*,6*S*)-(-)-1-(2'-Hydroxy-1'-phenyl-ethyl)-6-*n*-propylpiperidine-2-thione

Yellow oil


$[\alpha]_D^{20} = -107.2$ (*c* 3.9, CH_2Cl_2)



Yellow oil


$[\alpha]_D^{20} = +11.8$ (*c* 1.0, MeOH)

$C_{14}H_{18}INO$
(3*R*,5*S*)-(-)-5-Methyl-3-phenyl-2,3,5,6,7,8-hexahydro-oxazolo[3,2-*a*]pyridin-4-ylum iodide




Yellow oil
 $[\alpha]_D^{20} = +9.2$ (*c* 1.0, MeOH)

C₁₆H₂₂INO
(3*R*,5*S*)-(-)-5-Propyl-3-phenyl-2,3,5,6,7,8-hexahydro-oxazolo[3,2-*a*]pyridin-4-ylidium iodide




C₁₂H₁₈O₅N
2-Hydroxypinan-3-one

Ee = 99.0%
 $[\alpha]_D^{20} = -4.2$ (*c* 5.7, C₆D₆)
Source of chirality: (1*R*,2*R*,5*R*)
Absolute configuration: (2*S*,4*S*)




C₆H₁₂O₄N
2-Hydroxypinan-3-one

Ee = 99.0%
 $[\alpha]_D^{20} = -11.2$ (*c* 13.2, CD₃OD)
Source of chirality: (1*R*,2*R*,5*R*)
Absolute configuration: (2*S*,4*S*)



C₆H₁₂O₄N
2-Hydroxypinan-3-one


Ee = 99.0%
 $[\alpha]_D^{20} = +47.3$ (*c* 5.2, CD₃OD)
Source of chirality: (1*R*,2*R*,5*R*)
Absolute configuration: (2*S*,4*R*)



De = 99.8% (by HPLC)
 $[\alpha]_D^{20} = +331$ (*c* 1.3, benzene)
 Source of chirality: resolution
 Absolute configuration: (2*S*,3'*S*)




N-[*N'*-Phthaloyl-(2*S*)-alanyl]-[3*S*]-2,3-dihydro-3-methyl-4*H*-1,4-benzoxazine




De = 99.7% (by HPLC)
 $[\alpha]_D^{20} = +461$ (*c* 1.45, benzene)
 Source of chirality: resolution
 Absolute configuration: (2*S*,2'*S*)




N-[*N'*-Phthaloyl-(2*S*)-alanyl]-[3*S*]-2,3-methyl-1,2,3,4-tetrahydroquinoline




Ee = 96%
 $[\alpha]_D^{22} = -27.7$ (*c* 0.96, C₆H₆)
 Source of chirality: enzymatic
 desymmetrization
 Absolute configuration: *S*




(*S*)-5-[(Acetoxy)methyl]-5-(hydroxymethyl)tetrahydro-2-furanone



Ee ≥ 99%
 $[\alpha]_D^{22} = -16.0$ (*c* 1.32, C₆H₆)
 Source of chirality: enzymatic
 desymmetrization
 Absolute configuration: *S*



(*S*)-5-[(Tetradecanoyloxy)methyl]-5-(hydroxymethyl)tetrahydro-2-furanone



C₁₄H₂₆O₅Si


(S)-5-[(Acetyloxy)methyl]-5-[(tert-butyldimethylsiloxy)methyl]tetrahydro-2-furanone

Ee = 96%

[α]_D²² = -17.9 (c 1.34, C₆H₆)

Source of chirality: enzymatic
desymmetrization

Absolute configuration: R



C₁₂H₂₄O₄Si


(S)-5-[(tert-Butyldimethylsiloxy)methyl]-5-(hydroxymethyl)tetrahydro-2-furanone

Ee = 96%

[α]_D²² = -1.1 (c 1.07, C₆H₆)

Source of chirality: enzymatic
desymmetrization

Absolute configuration: R



C₂₆H₅₀O₅Si


(S)-5-[(tert-Butyldimethylsiloxy)methyl]-5-[(tetradecanoyloxy)methyl]tetrahydro-2-furanone

Ee = 96%

[α]_D²² = -11.6 (c 1.18, C₆H₆)

Source of chirality: enzymatic
desymmetrization

Absolute configuration: R



C₁₁H₁₂N₄O₂

(2S)-Azido-2-[2-phenyl-4,5-dihydro-oxazol-(4S)-yl]-ethanol


[α]_D²⁵ = -105 (c 1.6, CHCl₃)

Source of chirality: L-tartaric acid

Absolute configuration: (2S,4S)

Andreas Scheurer,* Walter Bauer, Frank Hampel, Christine Schmidt,
Rolf W. Saalfrank,* Paul Mosset,* Ralph Puchta and
Nico J. R. van Eikema Hommes

Tetrahedron: Asymmetry 15 (2004) 867



$[\alpha]_D^{25} = -12.6$ (*c* 1.5, CHCl₃)

Source of chirality: L-tartaric acid


Absolute configuration: (2*S*,4*S*)



p-Nitro-benzoic acid (2*S*)-azido-2-[2-phenyl-4,5-dihydro-oxazol-(4*S*)-yl]-ethyl ester

Andreas Scheurer,* Walter Bauer, Frank Hampel, Christine Schmidt,
Rolf W. Saalfrank,* Paul Mosset,* Ralph Puchta and
Nico J. R. van Eikema Hommes

Tetrahedron: Asymmetry 15 (2004) 867



$[\alpha]_D^{25} = -14.5$ (*c* 2.5, CHCl₃)

Source of chirality: L-tartaric acid


Absolute configuration: (2*S*,4*S*)



p-Bromo-benzoic acid (2*S*)-azido-2-[2-phenyl-4,5-dihydro-oxazol-(4*S*)-yl]-ethyl ester

Thomas G. Back,* Michael A. Bey, Masood Parvez and
Richard P. Pharis


Tetrahedron: Asymmetry 15 (2004) 873



$[\alpha]_D^{22} = +93.5$ (*c* 0.20, CH₃OH)

Source of chirality: resolution of an intermediate


Absolute configuration: (6*S*,7*R*,6'*S*,7'*R*)



(6*S*,7*R*,6'*S*,7'*R*)-1-[1-(4,6,7-Trihydroxy-5,6,7,8-tetrahydronaphthyl)]-2-[1'-(6',7'-dihydroxy-5',6',7',8'-tetrahydronaphthyl)]-ethyne

Thomas G. Back,* Michael A. Bey, Masood Parvez and
Richard P. Pharis

Tetrahedron: Asymmetry 15 (2004) 873



$[\alpha]_D^{22} = +4.2$ (*c* 0.10, CH₃OH)

Source of chirality: resolution of an intermediate


Absolute configuration: (6*S*,7*R*,6'*R*,7'*S*)



(6*S*,7*R*,6'*R*,7'*S*)-1-[1-(4,6,7-Trihydroxy-5,6,7,8-tetrahydronaphthyl)]-2-[1'-(6',7'-dihydroxy-5',6',7',8'-tetrahydronaphthyl)]-ethyne

Tetsutaro Hattori,* Hiroaki Iwato, Koichi Natori and Sotaro Miyano

Tetrahedron: Asymmetry 15 (2004) 881



C₃₄H₂₈O₄
(S_a,S_a)-2',6'-Dihydroxymethyl-2,2''-dimethoxy-1,1':5',1''-ternaphthalene


Ee = 100%

[α]_D²⁶ = -23.2 (c 0.10, CHCl₃)

Absolute configuration: (S_a,S_a)

Tetsutaro Hattori,* Hiroaki Iwato, Koichi Natori and Sotaro Miyano

Tetrahedron: Asymmetry 15 (2004) 881



C₃₄H₂₈O₄
(S_a,S_a)-2',3'-Dihydroxymethyl-2,2''-dimethoxy-1,1':4',1''-ternaphthalene


Ee = 100%

[α]_D²⁵ = +16.9 (c 0.40, CHCl₃)

Absolute configuration: (S_a,S_a)

Francesco Lazzaro, Marcello Crucianelli,* Francesco De Angelis, Massimo Frigerio, Luciana Malpezzi, Alessandro Volonterio and Matteo Zanda*

Tetrahedron: Asymmetry 15 (2004) 889



C₁₈H₂₄F₃NO₅S
(2R,R_S)-4-tert-Butyl 1-ethyl N-[(4-methylphenyl)sulfinyl]-2-(trifluoromethyl)aspartate

Ee = 97%


[α]_D²⁰ = -5.3 (c = 0.43, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (2R,R_S)

Francesco Lazzaro, Marcello Crucianelli,* Francesco De Angelis, Massimo Frigerio, Luciana Malpezzi, Alessandro Volonterio and Matteo Zanda*

Tetrahedron: Asymmetry 15 (2004) 889



C₇H₁₀F₃NO₄
(S)- α -Trifluoromethyl aspartic acid α -carboxy ethyl ester

Ee = 97%


[α]_D²⁰ = +22.4 (c = 0.52, H₂O)

Source of chirality: asymmetric synthesis

Absolute configuration: (S)

Francesco Lazzaro, Marcello Crucianelli,* Francesco De Angelis, Massimo Frigerio, Luciana Malpezzi, Alessandro Volonterio and Matteo Zanda*

Tetrahedron: Asymmetry 15 (2004) 889



C₅H₇ClF₃NO₄
(S)- α -Trifluoromethyl aspartic acid hydrochloride

Ee = 97%


[α]_D²⁰ = +23.5 (*c* = 0.25, H₂O)

Source of chirality: asymmetric synthesis

Absolute configuration: (S)

Francesco Lazzaro, Marcello Crucianelli,* Francesco De Angelis, Massimo Frigerio, Luciana Malpezzi, Alessandro Volonterio and Matteo Zanda*

Tetrahedron: Asymmetry 15 (2004) 889



C₅H₆F₃NO₄
(S)- α -Trifluoromethyl aspartic acid

Ee = 97%

[α]_D²⁰ = +23.5 (*c* = 0.17, H₂O)


Source of chirality: asymmetric synthesis

Absolute configuration: (S)

Minoru Ozeki, Kiyoharu Nishide, Fumiteru Teraoka and Manabu Node*

Tetrahedron: Asymmetry 15 (2004) 895

[α]_D²³ = +120.9 (*c* 0.88, CHCl₃)
99% ee




C₁₁H₁₆OS
(1*R*,3*S*)-1-Mercapto-1-phenyl-3-pentanol

Minoru Ozeki, Kiyoharu Nishide, Fumiteru Teraoka and Manabu Node*

Tetrahedron: Asymmetry 15 (2004) 895

[α]_D²⁵ = +105.7 (*c* 0.77, CHCl₃)
99% ee



C₁₅H₁₆OS
(1*R*,3*R*)-3-Mercapto-1,3-diphenyl-1-propanol